Japan plans to revise its definition of “vaccines of high development priority.” The Ministry of Health, Labor and Welfare’s (MHLW)…
REGULATORY
Big 4 Wholesalers Faced Wrath of FTC for Allocating Priority Drug Categories before Bidding
The Japan Fair Trade Commission (FTC) is pursuing its bid-rigging allegations over Big Four wholesalers because it sees it particularly problematic that the companies allocated their priority drug categories to share orders, an FTC official told Jiho on December 5.…
To read the full story
Related Article
- Mediceo Gets 6-Month Suspension from National Hospital Organization Bids
April 18, 2022
- Mediceo Dodged Charges and FTC Penalties, but Still Barred from JCHO Bids
April 12, 2022
- 3 Wholesalers Ordered to Pay 420 Million Yen in Surcharge over Bid-Rigging; JCHO to Suspend Mediceo Too
March 31, 2022
- FTC to Slap 3 Wholesalers with 420 Million Yen Surcharges over Bid-Rigging
February 7, 2022
- Guilty Rulings for 3 Wholesalers, Employees Now Final and Binding: Bid-Rigging Trial
July 19, 2021
- 3 Major Wholesalers, 7 Employees Found Guilty in Bid-Rigging Trial
July 2, 2021
- 300 Million Yen Fine Sought for Alfresa Too, Verdict on June 30: Bid-Rigging Trial
May 13, 2021
- 300 Million Yen Fine Sought for Toho Too, Court Decision Due June 2: Bid-Rigging Trial
April 30, 2021
- Prosecutors Seek 300 Million Yen Fine for Suzuken, Jail Terms for Employees: Bid-Rigging Trial
April 28, 2021
- 3 Indicted Wholesalers Barred from JCHO Bids for 2 Years: Bid-Rigging Scandal
December 14, 2020
- (Update) Criminal Charges Sought against 3 Wholesalers over Bid-Rigging, Mediceo Excluded
December 10, 2020
- Criminal Charges Sought against 3 Wholesalers over Bid-Rigging, Mediceo Excluded
December 9, 2020
- JPWA Raided Too over Big 4 Wholesalers’ Bid-Rigging Scandal
October 16, 2020
- Big 4 Wholesalers Now Suspected to Have Rigged Drug Prices in 2016 Too
October 14, 2020
- Big 4 Wholesalers Raided Again over Suspected Bid-Rigging
October 13, 2020
- JCHO Hospitals to Switch from Joint to Separate Bidding for Drug Purchases after Bid-Rigging Scandal
May 21, 2020
- “Tender Process Needs to Be Improved” in Response to Bid-Rigging Scandal by Top 4 Wholesalers: Hospital Management Advisor
February 25, 2020
- MHLW Bureau Chief Says Delay Would Be Inevitable to Revise Drug Distribution Guidelines as Bid-Rigging Probe Continues
January 17, 2020
- Wholesalers’ Bid-Rigging Scandal Might Have Been Exposed via Leniency Program, Further Cases Could Be Laid Bare: Lawyer
December 6, 2019
- Scandal-Hit JPWA Likely to Pass on Chuikyo’s Industry Hearing on Dec. 6
December 4, 2019
- Ryukaikon’s Dec. 9 Meeting Likely to Be Put Off in Wake of Bid-Rigging Scandal
December 3, 2019
- Stakeholders Rap Big 4 Wholesalers for Bid-Rigging Charges, Say Scandal Shutters Trust in Drug Price Surveys
November 29, 2019
- Big 4 Drug Wholesalers Raided on Bid-Rigging Charges
November 28, 2019
REGULATORY
- MHLW Orders Label Revisions for Lixiana, Keytruda, and More Drugs
January 30, 2025
- Pfizer’s Litfulo Braced for Price Cut after Cost-Effectiveness Assessment
January 30, 2025
- MHLW Panel Finalizes NIP Inclusion of Shingles Jabs, OKs New Basic Immunization Plan
January 30, 2025
- FPMAJ Reports Detailed Results of Blanket Self-Inspections for Generic Firms
January 29, 2025
- Celltrion Is Developer of Japan’s Third Stelara Biosimilar in the Wings
January 29, 2025
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…